September 6, 2011 — Stryker Corp. has signed a definitive agreement to acquire Concentric Medical for $135 million in an all-cash transaction. The acquisition provides Stryker with immediate entry into the fastest growing segment of the interventional neurovascular space.

September 6, 2011 — Mesoblast Ltd. announced it received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 European clinical trial for Revascor, its lead cardiovascular product. The study is being conducted in conjunction with angioplasty and stent procedures to gauge ability to prevent heart failure after a major heart attack.


September 1, 2011 – Mechanical pumps to give failing hearts a boost were originally developed as temporary measures for patients awaiting a heart transplant. But as the technology has improved, these ventricular assist devices commonly operate in patients for years, including in former vice-president Dick Cheney, whose implant this month celebrates its one-year anniversary.

September 1, 2011 – Results from CREDO-Kyoto PCI/CABG Registry Cohort-2 show that percutaneous coronary intervention (PCI) was associated with significantly higher risk for serious adverse events in patients with triple vessel disease than coronary artery bypass grafting (CABG). The protective effect of CABG for myocardial infarction was described as "especially remarkable." In view of these results, said investigator Hiroki Shiomi, M.D., from Kyoto University Hospital in Japan, "CABG would still remain the standard treatment option in patients with triple vessel disease, particularly when their SYNTAX scores are high.”

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now